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Abstract
Background: Glioblastoma multiforme (GBM) is the most frequently encountered brain cancer.
Although the existence of cancer stem cells in GBM has been previously established, there is little
evidence to explain the difference between cancer stem cells and radio-resistant cells in GBM. In
an effort to increase our understanding of whether cellular radio-resistance is a characteristic
associated with cancer stem cells, we developed a dissociated cell system of subpopulations derived
from GBM, and demonstrated radiotherapy resistance therein.
Results:  The radio-resistant cancer cell subpopulations of GBM abundantly express CD133,
CD117, CD71, and CD45 surface markers, and these radio-resistant cancer cell subpopulations
have the capacity for extensive proliferation, self-renewal, and pluripotency. These radio-resistant
cancer subpopulations have been shown to initiate tumorigenesis when transplanted into SCID
mouse brains. Moreover, these tumors evidenced highly peculiar nest-like shapes harboring both
vascular and cancerous tissue structures, which expressed the blood vessel specific marker, the von
Willebrand factor. Accordingly, subpopulations of radio-resistant cells in GBM have been shown to
be very similar to hematopoietic stem cells (HSCs) in the circulating blood. This similarity may
contribute to increased tumor growth and GBM recurrence.
Conclusion:  The results of the present study provide further evidence for radio resistant
subpopulations of cancer stem cells in GBM. Also, our results will assist in the identification and
characterization of cancer stem cell populations in glioma, and will help to improve the therapeutic
outcomes of GBM.
Background
In the past few years, it has been reported that cancers tend
to harbor small cell populations with the capability to sus-
tain tumor formation and growth in tumor cells. These
cells are referred to as cancer stem cells (CSCs) [1,2]. CSCs
have been identified in leukemia [3], multiple myeloma
[4] and breast cancer [5,6]. Recently, several studies have
demonstrated the existence of CSCs in human brain
tumors [7-9]. These CSCs shared many properties, includ-
ing self-renewal and multi-potency, with normal stem
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cells [10,11], and expressed a wide variety of transporters
involved in drug efflux [12-14]. Moreover, CSCs can initi-
ate tumors when transplanted into immune-deficient
mice [10,11].
As compared with other brain tumors, glioblastoma mul-
tiforme (GBM) is a relatively aggressive variant in humans
[15]. A combination of surgery, radiotherapy, and chem-
otherapy comprises the standard treatment in such cases
[16]. Despite constant efforts to develop prevention pro-
tocols for GBM, GBM is intrinsically resistant to conven-
tional therapies, including radiotherapy and
chemotherapy [12]. Singh et al. [11,17] previously iso-
lated a CD133+ cell population from glioma that evi-
denced properties of CSCs in vitro, and initiated tumors in
vivo. In a recent work conducted by Bao et al. [18], it was
shown that CD133+ glioma stem cells contributed to gli-
oma radioresistance via the preferential activation of DNA
damage checkpoint response and an increase in DNA
repair capacity as compared to CD133- tumor cells. There-
fore, the identification of the cell types involved in resist-
ance phenomena is critical from both a scientific and
therapeutic standpoint in cases of GBM. Although the
existence of cancer stem cells in GBM has been firmly
established, there is currently little evidence to explain the
difference between cancer stem cells and radio-resistant
cells in GBM. In this study, we have attempted to deter-
mine whether cellular radio-resistance is associated with
cancer stem cells in GBM. For a better understanding of
GBM, we developed a dissociated cell system to facilitate
the study of cancer stem cell subpopulations derived from
GBM, which evidenced resistance to radiotherapy. We
observed that radio-resistant cancer stem cell subpopula-
tions of GBM expressed CD133, CD117, CD71, and
CD45 cell surface markers, and also evidenced downregu-
lated neural marker expression. Also, these radio-resistant
stem cell subpopulations have been shown to initiate
tumorigenesis when stereotaxically transplanted into
SCID mouse brains. These findings provide further evi-
dence for the existence of radio-resistant subpopulations
in GBM CSCs. Our results will also help us to understand
the properties of radio-resistant subpopulation and help
to improve the therapeutic outcomes of GBM.
Results
Brain cancer cells have the resistant ability toward 
radiation
Radiation exposure has been shown previously to reduce
the survival rates of various glioblastoma cell lines –
including A172, U87MG, and GBM2. As is shown in Fig.
1, the majority of cells perished during the culture period,
leaving only a few surviving cells. After 3 passages of sub-
sequent applications, the survival rates of A172, GBM2,
and U87MG were 23, 42, and 30%, respectively (Fig. 1A).
The cell line most sensitive to radiation was A172, fol-
lowed by GBM2, whereas U87MG was the cancer cell line
most resistant to radiation. However, the surviving cells
proliferated with additional culture time. It was deter-
mined that small cell populations of the GBM cell lines
were resistant to radiation, and that these resistant cells
could actively proliferate. As is shown Fig. 2, the three
GBM cell lines evidenced spindle-shaped cells after radia-
tion, and progressively deteriorated and perished during
the culture periods. After radiation, only small cell popu-
lations evidencing a round morphology remained by the
end of the third culture period (Fig. 2). In addition, these
small cells proliferated and repopulated as the result of
subsequent cultures (Fig. 1A). Similarly in morphological
changes occurring in gamma-irradiated glioblastoma
cells, Erk1/2 and Akt phosphorylation was reduced in
A172, GBM2, and U87MG cells in the third culture period
post-radiation, but recovered in subsequent culture pas-
sages (Fig. 1B). These results showed that some of the cells
evidencing resistance to radiation in the GBM cell lines
were capable of proliferating via the activation of Erk1/2
and Akt. When the three types of GBM cells were treated
with gamma irradiation, apoptotic events were observed
via the TUNEL assay process (Fig. 3A). In addition, the
cleaved forms of caspase-3 and PARP were increased as the
result of radiation. Subsequently, Bax protein expression
was increased and Bcl-2 protein expression was attenuated
by gamma-irradiation at the same culture passage. How-
ever, these protein expressions were recovered over a pro-
longed culture period (Fig. 3B). It was suggested that the
radio-sensitive population of cancer cells inhibited the
growth of cells via the induction of apoptosis. On the
other hand, a few radio-resistant GBM cells survived and
proliferated after radiation, via an ability to escape apop-
tosis. In an effort to further determine whether radio-
resistant GBM cells are associated with cancer stem cells,
A172 and GBM2 cells were selected for subsequent exper-
iments, because these two types of cells were more sensi-
tive than U87MG.
Radio-resistant populations of brain cancer cells contain a 
stem cell-like subpopulation
Radio-resistant cancer cells of the A172 and GBM2 cell
lines were stained with fluorescence-conjugated primary
antibodies against surface markers for stem cells, CD133,
CD117, CD45, and CD71 according to the post-radiation
culture passage, and analyzed via flow cytometry. After
radiation, a variety of stem cell surface markers were
increased by culture passage, and their maximum rates
were achieved at the third culture passage (Fig. 4). As is
shown in Fig. 4B, radio-resistant A172 and GBM2 cancer
cells harbor 21.6 and 39.0% of CD133+, 52.4 and 46.5%
of CD117+, 51.2 and 37.6% of CD45+, 43.4 and 36.2%
of CD71+ cells, respectively. However, stains of the sur-
face markers on radio-resistant A172 and GBM2 cells were
decreased to control levels after further subcultures. It wasBMC Neuroscience 2008, 9:15 http://www.biomedcentral.com/1471-2202/9/15
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determined that a variety of stem cell-like subpopulation
cell types may exist in the population of radio-resistant
A172 and GBM2 cancer cells, and these may be capable of
proliferating on the stem-cell negative population layer.
To further evaluate the protein expression of radio-resist-
ant subpopulations in the cancer cell population, we con-
ducted double immunostaining analysis according to the
passages. The A172 and GBM2 cells were shown to express
markers for the NSC marker Nestin (31.0 and 44.8%), the
neuronal marker MAP2ab (29.3 and 16.2%), and the
astrocyte marker GFAP (39.7 and 39.0%) prior to radia-
tion (Fig. 5). However, the population of GFAP+ cells was
decreased significantly after radiation and the amount of
Nestin+ cells increased progressively up to the fifth culture
passage. These results showed that Nestin+ cells of A172
and GBM2 were more resistant then GFAP+ cells and
radio-resistant Nestin+ cells were capable of actively pro-
liferating.
Radio-resistant stem cell-like subpopulations of brain 
cancer cells have the ability to multipotency
The multipotency of individual radio-resistant stem cells-
like subpopulations within the A172 and GBM2 cancer
cells was directly evaluated via analysis of their neural dif-
ferentiation potentials (Fig. 6). Not only differentiated
radio-resistant stem cell-like subpopulations of A172 can-
cer cells evidenced immunoreactivity for hematopoietic
stem cell surface markers (including CD133, CD117,
CD71, and CD45) and nestin, but they also were able to
differentiate into GFAP-positive astrocyte-like cells, MBP-
positive myelin-like cells and MAP2ab-positive neuron-
like cells (Fig. 6). Conversely, in GBM2-derived radio-
resistant stem cell-like populations, CD133, CD117,
CD71, and CD45 cell surface epitopes coexhibited immu-
noreactivity for Nestin-positive cells, but lacked immuno-
reactivity for other differentiated neural cell markers,
including GFAP, MBP, and MAP2ab. These findings
showed that the stem cell-like population derived from
radio-resistant brain cancer cells evidences multipotency
and proliferation capacity, and those capacities were defi-
nitely different from control cancer cells.
The in vivo tumorigenic potential of radio-resistant cancer 
stem cell populations derived from brain cancer cells
In an effort to determine whether radio-resistant cancer
stem cell-like subpopulations of A172 and GBM2 cells
were capable of in vivo tumor initiation, we transplanted
these cells into SCID mouse brain tissue. Radio-resistant
cancer stem cell-like subpopulations derived from GBM
Cell proliferation of human glioblastoma cells by gamma-irradiation Figure 1
Cell proliferation of human glioblastoma cells by gamma-irradiation. The cell number was measured at various cul-
ture passages after gamma-irradiation through tryphan blue exclusion method. (A) Relative cell viability of A172, GBM2, and 
U87MG cells at various culture passages after gamma-irradiation. (B) Western blot analysis of total cell extractions isolated 
from human glioblastoma cells, A172 and GBM2, at various culture passages after gamma-irradiation. Results of triplicate sam-
ples were expressed as mean ± SD. **p < 0.01 vs control.
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cancer cell lines were shown to initiate tumor formation
below the cell injection site after 4 weeks (Fig. 7). As was
determined by hematoxylin and eosin staining, radio-
resistant cancer stem cell-like populations generated
highly peculiar nest-like tumors harboring both vascular
structure (Fig. 7B and 7E) and cancerous tissue structure
(Fig. 7C and 7F). The presence of both cell types in the
regenerated lesions indicates that lesions derived from the
brain cancer stem cells of radio-resistant glioblastoma
cells possess a profound capacity for multi-lineage differ-
entiation and the generation of blood vessels and tumor
masses in the brain.
The regenerated tumors evidenced immunoreactivity for
typical human-nuclei specific antigens (Fig. 8A–F) and for
the blood vessel-specific marker, von Willebrand factor
(Fig. 8G–N). Also, immunohistochemical analysis veri-
fied that these tumors were derived from engrafted radio-
resistant cancer stem cells and displayed a profound pro-
liferating activity, as evidenced by DAPI. Therefore, the
presence of regenerated tumors in transplanted SCID
mouse brain tissue suggested that the radio-resistant can-
cer cells possess a profound tumorigenic capacity.
Discussion and Conclusion
Glioblastoma multiforme (GBM) represents one of the
most frequently occurring brain cancers [15]. Besides sur-
gery, which is an important initial therapeutic measure in
cases of malignant glioma, postoperative radiotherapy,
including modern treatment techniques, is considered to
be the standard treatment in these cases [19-21]. Radia-
tion is the most frequently used in the treatment of GBM.
Today, the data from Walker et al [22], which indicated a
doubling of the median survival time in GBM from 4–5
months to 9–12 months with the application of postoper-
ative radiotherapy, remain valid. However, radiotherapy
does not appear to substantially prolong the median sur-
vival rates of GBM patients. Moreover, GBM harbored
subpopulations of cells with intrinsic resistance to radia-
tion, and these may be capable of repopulating tumors
after treatment [15]. In this study, we determined that
only a few A172, GBM2, and U87MG cells survived after
exposure to radiation (Fig. 1). After radiation, round-
shaped radio-resistant cells proved able to proliferate via
the activation of Erk1/2 and Akt (Fig. 1 and 2), whereas
the majority of spindle-shaped radio-sensitive cells con-
tinued to perish via apoptotic induction (Fig. 3). These
findings showed that the growth of the radio-sensitive
population of GBM cells was inhibited via apoptotic
induction. However, a few radio-resistant GBM cells sur-
Morphological change of human glioblastoma cells by gamma-irradiation Figure 2
Morphological change of human glioblastoma cells by gamma-irradiation. Phase microphotographs of cultured 
radio-resistant tumor cells of A172, GBM2, and U87MG cells (× 200 magnification) at various culture passages after gamma-
radiation. Scale bars, 50 μm.
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vived this process, and proliferated after radiation via their
ability to escape the apoptosis activation of the prolifera-
tion signals [23-25]. In a recent study, it was determined
that glioma stem cells contributed to glioma radioresist-
ance via the preferential activation of the DNA damage
checkpoint response [18] Therefore, further additional
studies will be required in order to elucidate the radiore-
sistance mechanisms of CSCs in GBM.
Recently, CSCs with a capacity of self-renewal and multi-
lineage differentiation have been isolated from tumors of
the human central nervous system (CNS) [7,8,25] These
cells harbor a small subpopulation and can generate all
kinds of mature cancer cell populations in culture [12].
The results of our FACS analyses showed that radio-resist-
ant GBM cells contain a variety of subpopulations, which
express CD133, CD117, CD45, and CD71 surface protein
(Fig. 4). In addition, double immunostaining showed
that Nestin-positive cells were more resistant to radiation
then GFAP- and MAP2ab-positive cells (Fig. 5). Further-
more, these individual radio-resistant cells were differen-
tiated into astrocytes, myelin, and neurons (Fig. 6). These
results showed that radio-resistant GBM subpopulations
are cancer stem cells with proliferation and pluripotency
abilities.
Numerous investigators have previously utilized antibod-
ies in order to cluster CD markers, thus characterizing and
isolating stem cells from a variety of tissues and cell types,
based on the profiles of their cell surface antigens. CD133,
CD117, and CD45 have been used to identify human
hematopoietic stem cells (HSCs) [25]. CD133, in particu-
lar, has been used as a marker of brain cancer stem cells,
because the subpopulation of CD133+ cells from human
brain tumors has been shown to harbor stem cell proper-
ties for proliferation, self-renewal, and differentiation in
vivo, and can also initiate tumors in vitro [11,17]. In our
study, we determined that radio-resistant cancer stem cell-
Apoptotic cell death of human glioblastoma cells as the result of gamma-irradiation Figure 3
Apoptotic cell death of human glioblastoma cells as the result of gamma-irradiation. (A) TUNEL assays of A172, 
GBM2, and U87MG cells following gamma-irradiation (× 200 magnification). Arrows indicate the apoptotic deaths of the tumor 
cells. (B) Western blot analysis of total cell extractions isolated from A172 and GBM2 at various culture passages after gamma-
irradiation. Scale bars, 50 μm.
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like subpopulations derived from GBM were primarily
Nestin-positive cells which abundantly expressed CD133,
CD117, CD45, and CD71 cell surface markers (Fig. 4 and
5). In addition, these radio-resistant cancer stem cell-like
subpopulations can initiate tumor and vascular genera-
tion when transplanted into SCID mouse brains using the
stereotaxic system (Fig. 7 and 8). These findings indicated
that CD117, CD45, and CD71, as well as CD133, can be
novel markers for human GBM.
Because CD133-positive populations of brain cancer cells
were also detected in normal neural stem cells, the cell of
origin for a given brain tumor may be normal stem cells
[15,26]. Multiple reports have indicated that rodent and
human bone marrow (BM) and BM-HSCs can acquire
neural cell fates both in vitro and in vivo [27-30]. Cancer
stem cells are thought to be derived from their normal
stem cell counterparts [17]. However, our immunohisto-
chemical results showed that radio-resistant stem cell-like
subpopulations from GBM evidenced a lack of immuno-
reactivity against Nestin for neural stem cell types, GFAP
for astrocytic cells, and MAP2ab for neurons, according to
the culture periods employed (Fig. 6). Furthemore, regen-
erated tumors in SCID mouse brain tissue were shown to
contain vascular structures in addition to cancerous tissue
structures (Fig. 7), and also exhibited immunoreactivity
Surface markers expressions of radio-resistant cells derived from human glioblastoma cells Figure 4
Surface markers expressions of radio-resistant cells derived from human glioblastoma cells. The cultured radio-
resistant cells (1 × 106) were stained with CD133, CD117, CD45, and CD71 coupled to fluorescein isothiocyanate (FITC) or 
PE (phycoerythrin) at various culture passages after gamma-irradiation, and then analyzed via flow cytometry. (A) Each cell sub-
population rate of A172 cells after gamma-irradiation. (B) Representative flow cytometry histogram of radio-resistant A172 
subpopulations for CD133, CD117, CD45 and CD71 at three culture passages after gamma-irradiation. (C) Each cell subpopu-
lation rate of GBM2 cells after gamma-radiation. (D) Representative flow cytometry histogram of radio-resistant GBM2 sub-
populations for CD133, CD117, CD45 and CD71 at three culture passages after gamma-radiation. The results of triplicate 
samples were expressed as the means ± SD. **p < 0.01 vs control.
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for the blood vessel-specific marker, von Willebrand fac-
tor (Fig. 8). Similar findings were reported by Massengale
et al. [31], who determined that hematopoietic stem cells
(HSCs) that enter the adult mouse brain become micro-
glia or evidence other hematopoietic cell fates, and their
progeny retain lineage fidelity within the CNS. In a recent
work conducted by Salmaggi et al. [32], it was shown that
GBM-derived CSCs contributed to glioma angiogenesis
via secretions of vascular endothelial growth factor
(VEGF) and CXCL12. Therefore, in our present study, it
was shown that radio-resistant stem-like GBM cells are
quite similar to HSCs in circulating blood, and they may
exacerbate tumor growth and the recurrence of GBM in
the brain.
In this study, we developed a dissociated cell system to
facilitate the identification and characterization of cancer
stem cell subpopulations of GBM evidencing radiother-
apy resistance. We also created a model that can be effi-
ciently used for the study of the tumorigenesis properties
of cancer stem cells. The cellular heterogeneity of GBM
indicated that radio-resistant subpopulations of GBM
stem cells expressed CD133, CD117, CD71, and CD45
cell surface markers, and that these radio-resistant cancer
stem cell subpopulations are capable of regenerating
tumors in vivo. Finally, we are able to conclude that radio-
resistant cancer stem cells are likely to be the most critical
target in treatments for GBM, and a thorough understand-
ing of its biology might allow it to be selectively targeted,
thereby greatly improving therapeutic outcomes. Addi-
tionally, the notion that the radio-resistant subpopulation
of GBM cells is derived from cancer stem cells might result
in the development of new strategies for the development
of anticancer therapies.
Immunocytotochemical characteristics of radio-resistant cells derived from human glioblastoma cells Figure 5
Immunocytotochemical characteristics of radio-resistant cells derived from human glioblastoma cells. Cells 
were labeled with antibodies to Nestin (green) or MAP2ab (green) to recognized neurons or GFAP (red) to recognized glia at 
various culture passages after gamma-irradiation. (A) Fluorescence microscope images (× 200 magnification) and relative pro-
tein expression of radio-resistant A172 cells over the culture passages. (B) Fluorescence microscope images (× 200 magnifica-
tion) and relative protein expression of radio-resistant GBM2 cells over the culture passages. The results of triplicate samples 
were expressed as the means ± SD. **p < 0.01 vs control. Scale bars, 50 μm.
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Methods
Animals
Female NOD-SCID mice (5-week-old females) were pur-
chased from the Jackson Laboratory. The animals were
kept under day/night rhythm and were fed as labium
throughout the experimental period. The Pusan National
University Committee on Animal Research approved the
experimental procedures.
Cell line and culture conditions
Human glioblastoma multiforme cell lines, A172 and
U87MG were obtained from American Type Culture Col-
lection (ATCC, Manassas, USA). The glioblastoma multi-
forme-derived cell line GBM2 was established in the
author's laboratory from a surgical specimen of a 62-old-
man. The cells were maintained in Dubelcco's modified
Egale's medium (Gibco, USA) supplemented with 10%
FBS (Gibco, USA) and 100 units/ml penicillin-streptomy-
cin (Gibco, USA). In all experiments, cells were main-
tained in 100-mm culture dishes at 37°C i na humidified
5%/CO2 95% air atmosphere. GBM2, established cell line
from tumor specimen of patients were used at passage
30–35 for the experiments. All of our experiments were
performed on cultures that were at 70% confluence, when
cells still in log phase growth.
In vitro differentiation and cell surface marker coexpression of radio-resistant cells derived from human glioblastoma cells Figure 6
In vitro differentiation and cell surface marker coexpression of radio-resistant cells derived from human gliob-
lastoma cells. Cells were labeled with antibodies for neuronal (Tuj and MAP2ab; red), glial (GFAP; red), and neural stem cells 
(Nestin; red), and cell surface epitopes (CD133, CD117, and CD45; green), and were then observed via laser scanning confocal 
microscopy. (A) Laser scanning images of differentiation and CD133 cell surface marker coexpression of radio-resistant human 
glioblastoma A172 and GBM2 cells. (B) Laser scanning images of differentiation and CD117 cell surface marker coexpression of 
radio-resistant human glioblastoma A172 and GBM2 cells. (C) Laser scanning images of differentiation and CD133 cell surface 
marker coexpression of radioresistant human glioblastoma A172 and GBM2 cells. (D) Laser scanning images of differentiation 
and CD71 cell surface marker coexpression of radioresistant human glioblastoma A172 and GBM2 cells. Images represent × 
400 magnification. Scale bars, 25 μm.
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Radiation exposure
Radiation was performed with a Leksell Gamma Knife
(Model 23004 B-2, Elekta Instruments, Sweden) using a
60Co gamma source, a dose intensity of 3.14 Gy/min and
400 mm distance between source and target up to a single
dose of 30 Gy. We used three kinds of cultured glioblast-
oma cells, GBM2, A172, and U87MG cells and volume
was 4 mm and maximal irradiation dose was 30 Gy per
sample. After irradiation, the cells were seeded at 1.0 × 106
cells/10 cm culture dish in 10 ml DMEM supplemented
with 10% FBS. The irradiation culture dishes were usually
split twice per week and replaced with the medium con-
taining 10% FBS during subculture. At different time peri-
ods (culture passage) after irradiation, the cell number
was measured using tryphan blue exclusion method.
TUNEL (TdT-mediated dUTP-biotin nick end-labeling) 
assay
The effect of gamma irradiation on the induction of apop-
tosis was detected with the TdT in situ Apoptosis Detec-
tion Kit (Roche, USA), according to the manufacturer's
specifications. After irradiation, three types of glioblast-
oma cells (1 × 105 cells) were cultured in chamber slide
with DMEM containing 10% FBS for 24 h. Then, the cells
were fixed with 4% paraformaldehyde. After washing with
PBS, the cells were incubated in TUNEL reaction mixture
(TdT-mediated dUTP-X nick end labeling). And then incu-
bated secondary antibody conjugated a biotin to enable
visualization of the fluorescent markers for light micros-
copy.
FACS analysis
For analysis of subpopulation in the cancer cell lines, the
cultured cells were removed from the culture dish with
trypsin containing EDTA and washed with PBS. The cells
were then labeled with CD133 (Miltenyi Biotec, Ger-
many), CD117 (BD Pharmingen, USA), CD45 (BD
Pharmingen, USA), and CD71 (Chemicon, USA) at 4°C
for 30 min. Then 1 × 105 cells were analyzed in a FACS-
Vantage fluorescence-activated cell sorter (Beton Dickin-
In vivo tumorigeneisis of radio-resistant cells derived from human glioblastoma cells by transplanted subpopulation in SCID  mouse Figure 7
In vivo tumorigeneisis of radio-resistant cells derived from human glioblastoma cells by transplanted subpopu-
lation in SCID mouse. Mice were transplanted with radio-resistant A172 cells (A-C) or GBM2 cells (D-F) into the right 
striatum via stereotaxic injection, and sacrificed at 4 weeks post-transplantation. Frozen sections of brain tumors were stained 
with hematoxylin and eosin. (A and F) Peculiar tumor mass-like structure (arrow) and blood vascular formation derived from 
radio-resistant A172 cells (A, × 40 magnification; B, × 100 magnification) and radio-resistant GBM2 cells (D, × 40 magnification; 
E, × 100 magnification). (C and F) Solid tumor formation derived from radio-resistant A172 cells (C, × 100 magnification) and 
radio-resistant GBM2 cells (F, × 200 magnification). Scale bars, 100 μm.
A172
GBM2
A BC
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son, San Jose, CA). For an isotype control, nonspecific
mouse IgG (BD Pharmingen, USA) was substituted for the
primary antibody. After immunocytochemistry of cell sur-
face epitopes we analyzed positive cells using Fluores-
cence Microscope (Leica Microsystems, PA).
Immunocytochemistry analysis
For analysis of protein expression of neuronal and glial
markers in radio-resistant cancer cells, radio-resistant
glioblastoma cells were fixed with 4% paraformaldehyde
fixative solution for 30 min at room temperature. After
washing with PBS, cells were incubated with primary anti-
bodies against anti-MBP (1:3000, Chemicon, USA), anti-
GFAP (1:1500, DAKO Cytomation, Denmark), anti-Nes-
tin (1:200, Sigma, USA), anti-MAP2ab (1:200, Sigma,
USA), anti-CD133 (1:10), anti-CD117 (1:10), and anti-
CD45 (1:10) overnight at 4°C. After extensive washing
with PBS, the cells were incubated for 30 min with FITC,
Texas-Red, or TRITC conjugated secondary antibodies
(1:250, Molecular Probe, USA). Cell nuclei were labeled
with 4–6'diamidino-2-phenylindoline (DAPI; Vector lab-
oratories, UK) and Topro-3 (Molecular Probe, USA). We
analyzed using Fluorescence Microscope (Leica Microsys-
tems, PA) and Confocal Microscopy (Leica Microsystems,
Immunocytochemical characteristics of brain tumor mass from SCID mouse transplanted with radio-resistant cancer stem cells  derived from human gliobalstoma cells Figure 8
Immunocytochemical characteristics of brain tumor mass from SCID mouse transplanted with radio-resistant 
cancer stem cells derived from human gliobalstoma cells. Frozen sections of brain tumors were labeled with antibod-
ies to human-nuclei to recognize engrafted human gliobalstoma cells (Red) or von Willebrand factor to recognize blood vessels 
(Green). Fluorescence microscope images of solid tumors from brain tissue transplanted with radio-resistant A172 (C-F) and 
GBM2 (G-J) cells. (A-B) Demonstrates a human-nuclei (red) and von Willebrand factor of solid tumors as the result of trans-
plantation with radio-resistant cells (× 100 magnification). The sections were also labeled with DAPI (blue) to identify nuclei. 
Laser scaning confocal images of blood vascular tissue from brain samples by transplantation with radio-resistant A172 (C-F) 
and GBM2 (G-J) cells (× 100 magnification). (C-J) Demonstrates a von Willebrand factor (green), human-nuclei (red) of blood 
vascular, and TOPRO-3 (blue) derived from radio-resistant A172 (C-F) and GBM2 (G-J) cells (× 100 magnification). G and K 
are merged Confocal images derived from radio-resistant A172 (C) and GBM2 (G) cells, respectively. Scale bar, 50 μm.BMC Neuroscience 2008, 9:15 http://www.biomedcentral.com/1471-2202/9/15
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PA) using a Leica TCS sp2 laser scanning microscope
equipped with 3 lasers. Immunocytochemical experi-
ments were repeated at least three times.
RT-PCR analysis of radio-resistant glioblastoma cells
After gamma-irradiation, cells were harvested with pas-
sages, and total cellular RNA was extracted with Trizol
(Invitrogen, USA) reverse transcribed into first strand
cDNA using oligo-dT primer (Promega, USA) an ampli-
fied by 35 cycles (94°C, 1 min; 55°C, 1 min; 72°C, 1
min) of PCR using 20 pM of specific primers. PCR ampli-
fication was performed using the primer sets. All primer
sequences were determined using established human
GeneBank sequences for genes indicative of neural line-
ages or control genes. Expression of the following mole-
cules was detected by RT-PCR: Nestin (5'-
ACCAAGAGACATTCAGACTCC; 3'-CCTCATCCTTATTT-
TCCACTCC; 302 bp), Sox-2 (5'-TACCTCTTCCTC-
CCACTCCA; 3'-ACTCTCCTCTTTTGCACCCC; 269 bp),
Notch-1 (5'-CAGGCATACCGAGGACTATG; 3'-CAG-
GCGTGTTGTTCTCACAG; 428 bp), FGFR-1 (5'-GGAG-
GATCGAGCTCACTCGTGG; 3'-
CGGAGAAGTAGGTGGTGTCAC; 428 bp), EGFR (5'-
CTTCTTGCAGCGATACAGCTC; 3'-ATGCTCCAATAAAT-
TCACTGC; 441 bp), GFAP (5'-GCTCGATCAACTCAC-
CGCCAAC A; 3'-GGGCAGCAGCGTCTGTCAGGTC; 430
bp), MAP2ab (5'-CAGCAAAGGGATACTTT CAC; 3'-
ATGCTTTTTGTTGCTTCTTC; 496 bp), VEGF (5'-ACATCT-
TCCAGGAGTACCCT GATGAG; 3'-GCATTCACATTTGTT-
GTGCTGT; 204 bp), and GAPDH(5'-
ATCAGCACAGTCCATGCCATCACT; 3'-TGAGGTCCAC-
CACCCTGTTGCTGTA; 460 bp).
Immunoblot analysis
We performed sonication of cells in 500 μl of lysis buffer
(20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA,
1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
EGTA, 1 mM glycerophosphate, 1 mM Na3VO4, 1 mM
PMSF). Lysates were clarified by centrifugation at 15,000
× g for 10 min and the total protein content was deter-
mined. Equal amounts (30 μg) of protein extracts in lysis
buffer were subjected to 10% SDS-PAGE analysis and
transferred to the nitrocellulose membrane. Anti-PARP,
anti-cleaved caspase-3, anti Akt, anti phosphorylated Akt,
anti-Erk1/2 and anti phosphorylated-Erk1/2 antibodies
were purchased from Cell Signaling Technology Inc.
(USA). Anti Bcl 2, and anti Bax antibodies were purchased
form Santa Cruz (USA). Anti actin antibody was from
Sigma Chemical Co. (USA). Enhanced chemo-lumines-
cence (ECL, Amersham-Pharmacia, UK) system was used
for detection. Relative band intensities were determined
by quantitation of each band with Quantity-one 1-D anal-
ysis software (Bio-Rad, USA).
In vitro differentiation to neural cells of radioresistant 
glioblastoma cells
To assess for multipotency, radio-resistant GBM2, A172
and U87MG cells were plated at a density of 2.5 × 104
cells/cm2 onto fibronection-coated glass coverslips (12
mm diameter) in Neurobasal medium (NB, Invitrogen,
USA) containing B27 supplement (Invitrogen, USA), 2%
FBS, and 10 ng/ml Retinoic acid (RA, Sigma, USA) for 7 to
10 days according to various time periods (culture pas-
sage) of post radiation. Retinoic acid was treated every 2
days.
Evaluation of tumorigenicity by stereotaxic injection
Tumorigenicity was determined by stereotaxic injection of
radio-resistant subpopulation of human glioblastoma
multiforme-derived A172 and GBM2 cells. Athymic SCID
mice were anesthetized with i.p. ketamine and each cells
(5 × 105) were labeled with CFDA-SE cell tracer kit
(Chemicon, USA) before transplantation. Cells in 10 ul of
HBSS were delivered into the right striatum (0.1 μl/min)
by stereotaxic injection through a glass electrode con-
nected to a Hamilton syringe. The following coordinates
were used: anterior-posterior = 0; median-lateral = 2.4
mm dorsal-ventral = 2.6 mm. The mice were sacrificed at
4 weeks post-transplantation. The mouse brains were
immediately fixed with 4% paraformaldehyde and
embedded in Tissue-Tek OCT (optimal culture tempera-
ture) compound, and then frozen at -20°C. 10 μm coro-
nal sections were cut through the brain using a freezing
microtome (CM3050; Leika Microsystems, PA) and
mounted on poly-D-Lysine-coated slides. Hematoxylin
and eosin staining and immunohistochemistry were per-
formed on 10 um-thick cryostat sections. Sections were
processed as by Vescovi et al. [33].
Immunohistochemistry on tumor sections
Frozen sections were stained with hematoxylin and eosin
(H&E). For visualization of transplanted cells, frozen sec-
tions were air-dried, fixed in 4% paraformaldehyde, and
mounted in mounting medium containing DAPI. For
determine the coexpression of tumor lesions and trans-
planted human cells by fluorescent staining after immu-
nohistochemistry, frozen sections were stained with anti-
mouse von Willebrand factor (1:1000, Chemicon, USA)
and anti-human nuclei (1:200, Chemicon, USA) for over-
night at 4°C. After washing with PBS, the tumor sections
were incubated for 30 min with FITC and TRITC conju-
gated secondary antibodies (1:250, Molecular Probe,
USA). Cell nuclei were labeled with TOPRO-3 (Molecular
Probe, USA). Then we analyzed using Fluorescence Micro-
scope (Leica Microsystems, PA) and Confocal Microscopy
(Leica Microsystems, PA) using a Leica TCS sp2 laser scan-
ning microscope equipped with 3 lasers.BMC Neuroscience 2008, 9:15 http://www.biomedcentral.com/1471-2202/9/15
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Statistical analysis
The statistical significance of difference between groups
was calculated by applying the Student's two-tailed t-test.
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